The shares of Genworth Financial, Inc. (NYSE:GNW) has been pegged with a rating of Market Perform by Wells Fargo in its latest research note that was published on September 23rd, 2016. Wells Fargo wasn’t the only research firm that published a report of Genworth Financial, Inc., with other equities research analysts also giving their opinion on the stock. Compass Point advised investors in its research note published on May 5th, 2016, to Buy the GNW stock while also putting a $5.25 price target. The stock had earned Buy rating from Compass Point when it published its report on February 8th, 2016. That day the Compass Point set price target on the stock to $5.50. The stock was given Neutral rating by Goldman in its report released on November 17th, 2015, the day when the price target on the stock was placed at $5. UBS was of a view that GNW is Sell in its latest report on November 4th, 2015 while giving it a price target of $4.25. UBS thinks that GNW is worth Neutral rating. This was contained in the firm’s report on September 8th, 2015 in which the stock’s price target was also moved to $5.25.
Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 4 believe it has the potential for further growth, thus rating it as Hold while 0 advised investors to purchase the stock. The consensus currently stands at a Hold while its average price target is $4.50. The price of the stock the last time has raised by 80.45% from its Week high price while it is raised higher than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 60.96.
The shares of the company added by 0.63% during the trading session on Friday, reaching a low of $4.7 while ending the day at $4.80. During the trading session, a total of 2.78 million shares were traded which represents a 41.36% incline from the average session volume which is 4.74M shares. GNW had ended its last session trading at 4.77. Genworth Financial, Inc. currently has a market cap of $2.40B, while its P/E ratio stands at 6.46, while its P/E earnings growth sits at 0.30, with a beta of 1.68. Genworth Financial, Inc. debt-to-equity ratio currently stands at 0.34, while its quick ratio hovers at . GNW 52-week low price stands at $2.66 while its 52-week high price is $4.93.
The company in its last quarterly report recorded $0.29 earnings per share which is above the $0.26 predicted by most analysts. The Genworth Financial, Inc. generated $2,143.00 million in revenue during the last quarter, which is slightly lower than the $2,163.00 million predicted by analysts. In the second quarter last year, the firm recorded $0.40 earnings per share. Compared to the same quarter last year, the firm’s revenue was down by -37.93%. Genworth Financial, Inc. has the potential to record 0.74 EPS for the current fiscal year, according to equities analysts.
Investment analysts at Argus published a research note on November 14th, 2018 where it informed investors and clients that Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) is now rated as Hold. Compass Point also rated MDRX as Reiterated on May 5th, 2016, with its price target of $5.25 suggesting that MDRX could surge by 14.79% from its current share price. Even though the stock has been trading at $11.37/share, analysts expect it to surge higher by 0.35% to reach $13.39/share. It started the day trading at $11.68 and traded between $11.2 and $11.41 throughout the trading session.
A look at its technical shows that MDRX’s 50-day SMA is 10.12 while its 200-day SMA stands at 12.28. The company’s average trading volume currently stands at 2.63M shares, which means that the short-interest ratio is just 5.71 days. Over the past seven days, the company moved, with its shift of 12.97%. Looking further, the stock has dropped -15.42% over the past 90 days while it lost -6.86% over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. Wellington Management Co LLP bought more MDRX shares, increasing its portfolio by +1.28% during the last quarter. This move now sees Wellington Management Co LLP purchasing 247,623 shares in the last quarter, thus it now holds 19,594,880 shares of MDRX, with a total valuation of $188,894,643. BlackRock Fund Advisors meanwhile sold more MDRX shares in the recently filed quarter, changing its stake to $174,619,548 worth of shares. The Vanguard Group Inc followed the path by increasing its MDRX portfolio by +1.03% in the quarter. This means that The Vanguard Group Inc bought 159,111 shares in the last quarter and now controls 15,654,165 shares of the MDRX stock, with the valuation hitting $150,906,151.
Similarly, Fuller Thaler Asset Management decreased its Allscripts Healthcare Solutions, Inc. shares by -2.22% during the recently filed quarter. After selling -151,748 shares in the last quarter, the firm now controls 6,684,904 shares of Allscripts Healthcare Solutions, Inc. which are valued at $64,442,475. In the same vein, Fiduciary Management Inc decreased its Allscripts Healthcare Solutions, Inc. shares by during the most recent reported quarter. The firm sold -117,960 shares during the quarter which decreased its stakes to 6,568,851 shares and is now valued at $63,323,724. Following these latest developments, around 1.70% of Allscripts Healthcare Solutions, Inc. stocks are owned by institutional investors and hedge funds.